As of 2025-12-13, the Intrinsic Value of ImmuPharma PLC (IMM.L) is -9.79 GBP. This IMM.L valuation is based on the model Peter Lynch Fair Value. With the current market price of 6.20 GBP, the upside of ImmuPharma PLC is -257.88%.
Based on its market price of 6.20 GBP and our intrinsic valuation, ImmuPharma PLC (IMM.L) is overvalued by 257.88%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -9.79 - -9.79 | -9.79 | -257.88% |
| P/E | (10.19) - (10.84) | (12.56) | -302.6% |
| DDM - Stable | (3.82) - (10.58) | (7.20) | -216.2% |
| DDM - Multi | (1.97) - (4.51) | (2.77) | -144.7% |
| Market Cap (mil) | 30.16 |
| Beta | 0.43 |
| Outstanding shares (mil) | 4.87 |
| Enterprise Value (mil) | 29.77 |
| Market risk premium | 5.98% |
| Cost of Equity | 14.85% |
| Cost of Debt | 5.00% |
| WACC | 9.65% |